IGF1 and schizophrenia: In schizophrenia (SZ), Down Syndrome, and bipolar disorder (BD), increased brain insulin resistance and reduced IGF-1 signaling drive allostatic load/overload, leading to physiological dysregulation and the presentation of more severe symptoms throughout the body [44,45,46].